H1 25 Results: Increased Profitability Despite Subdued Revenues
medmix (SIX: MEDX) reported H1 2025 results showing improved profitability despite revenue challenges. Revenue declined to CHF 225.4 million (-6.5% YoY), with Healthcare segment growing 7.5% while Consumer & Industrial segment declined 10.9% organically.
Key financial metrics include adjusted EBITDA margin of 19.9% (+80 bps YoY), segment gross profit margin improvement of 390 bps to 47.9%, and Free Cash Flow of CHF 11.4m (+50.9% YoY). The company's Growth and Efficiency program secured CHF 15 million in savings, with CHF 8.5m realized in H1 2025.
Management revised 2025 revenue guidance to expect a decline similar to H1 2025, while maintaining adjusted EBITDA margin guidance of 18-19%. Mid-term guidance remains unchanged with revenue CAGR above 4% and adjusted EBITDA margin above 20%.
medmix (SIX: MEDX) ha comunicato i risultati del primo semestre 2025, evidenziando un miglioramento della redditività nonostante le difficoltà nei ricavi. Il fatturato è diminuito a CHF 225,4 milioni (-6,5% su base annua), con il segmento Healthcare in crescita del 7,5%, mentre il segmento Consumer & Industrial ha registrato un calo organico del 10,9%.
I principali indicatori finanziari includono un margine EBITDA rettificato del 19,9% (+80 punti base su base annua), un miglioramento del margine lordo di segmento di 390 punti base, raggiungendo il 47,9%, e un Free Cash Flow di CHF 11,4 milioni (+50,9% su base annua). Il programma di Crescita ed Efficienza dell'azienda ha garantito risparmi per CHF 15 milioni, di cui CHF 8,5 milioni realizzati nel primo semestre 2025.
Il management ha rivisto le previsioni di fatturato per il 2025, prevedendo un calo simile a quello del primo semestre 2025, mantenendo però la guidance sul margine EBITDA rettificato tra il 18% e il 19%. Le previsioni a medio termine restano invariate, con un CAGR dei ricavi superiore al 4% e un margine EBITDA rettificato superiore al 20%.
medmix (SIX: MEDX) presentó los resultados del primer semestre de 2025 mostrando una mejora en la rentabilidad a pesar de los desafíos en los ingresos. Los ingresos disminuyeron a CHF 225,4 millones (-6,5% interanual), con el segmento de Salud creciendo un 7,5%, mientras que el segmento de Consumo e Industrial cayó un 10,9% de forma orgánica.
Las métricas financieras clave incluyen un margen EBITDA ajustado del 19,9% (+80 puntos básicos interanual), una mejora en el margen bruto del segmento de 390 puntos básicos hasta el 47,9%, y un Flujo de Caja Libre de CHF 11,4 millones (+50,9% interanual). El programa de Crecimiento y Eficiencia de la empresa aseguró ahorros por CHF 15 millones, con CHF 8,5 millones realizados en el primer semestre de 2025.
La dirección revisó la guía de ingresos para 2025 esperando una caída similar a la del primer semestre de 2025, manteniendo la guía del margen EBITDA ajustado entre el 18% y el 19%. La guía a medio plazo permanece sin cambios, con un CAGR de ingresos superior al 4% y un margen EBITDA ajustado por encima del 20%.
medmix (SIX: MEDX)는 2025년 상반기 실적을 발표하며 매출 부진에도 불구하고 수익성이 개선되었음을 보였습니다. 매출은 CHF 2억 2540만 (-6.5% 전년 대비)으로 감소했으며, 헬스케어 부문은 7.5% 성장한 반면, 소비재 및 산업 부문은 유기적으로 10.9% 감소했습니다.
주요 재무 지표로는 조정 EBITDA 마진 19.9% (+80bps 전년 대비), 부문별 총이익률 47.9%로 390bps 개선, 그리고 자유현금흐름 1,140만 CHF (+50.9% 전년 대비)가 포함됩니다. 회사의 성장 및 효율성 프로그램은 1,500만 CHF의 비용 절감을 확보했으며, 이 중 850만 CHF가 2025년 상반기에 실현되었습니다.
경영진은 2025년 매출 가이던스를 2025년 상반기와 유사한 감소를 예상하며 조정 EBITDA 마진 가이던스는 18-19%로 유지했습니다. 중기 가이던스는 변함없이 매출 연평균 성장률 4% 이상과 조정 EBITDA 마진 20% 이상을 목표로 하고 있습니다.
medmix (SIX : MEDX) a publié ses résultats du premier semestre 2025, montrant une amélioration de la rentabilité malgré des défis au niveau du chiffre d'affaires. Le chiffre d'affaires a diminué à 225,4 millions de CHF (-6,5% en glissement annuel), avec une croissance de 7,5% dans le segment Santé, tandis que le segment Consommation & Industrie a enregistré une baisse organique de 10,9%.
Les principaux indicateurs financiers comprennent une marge EBITDA ajustée de 19,9% (+80 points de base en glissement annuel), une amélioration de la marge brute par segment de 390 points de base à 47,9%, et un flux de trésorerie disponible de 11,4 millions de CHF (+50,9% en glissement annuel). Le programme de Croissance et d’Efficacité de l’entreprise a permis des économies de 15 millions de CHF, dont 8,5 millions réalisés au premier semestre 2025.
La direction a révisé ses prévisions de chiffre d'affaires pour 2025, anticipant une baisse similaire à celle du premier semestre 2025, tout en maintenant l’objectif de marge EBITDA ajustée entre 18 % et 19 %. Les prévisions à moyen terme restent inchangées, avec un TCAC du chiffre d'affaires supérieur à 4 % et une marge EBITDA ajustée supérieure à 20 %.
medmix (SIX: MEDX) berichtete über die Ergebnisse des ersten Halbjahres 2025 und zeigte trotz Umsatzherausforderungen eine verbesserte Rentabilität. Der Umsatz sank auf CHF 225,4 Millionen (-6,5% im Jahresvergleich), wobei das Healthcare-Segment um 7,5% wuchs, während das Consumer & Industrial-Segment organisch um 10,9% zurückging.
Wichtige Finanzkennzahlen umfassen eine bereinigte EBITDA-Marge von 19,9% (+80 Basispunkte im Jahresvergleich), eine Verbesserung der Bruttomarge des Segments um 390 Basispunkte auf 47,9% sowie einen Free Cash Flow von CHF 11,4 Mio. (+50,9% im Jahresvergleich). Das Wachstums- und Effizienzprogramm des Unternehmens erzielte CHF 15 Millionen Einsparungen, davon wurden CHF 8,5 Mio. im ersten Halbjahr 2025 realisiert.
Das Management hat die Umsatzprognose für 2025 überarbeitet und erwartet einen Rückgang ähnlich dem des ersten Halbjahres 2025, behält jedoch die Prognose für die bereinigte EBITDA-Marge von 18-19% bei. Die mittelfristige Prognose bleibt unverändert mit einem Umsatz-CAGR von über 4% und einer bereinigten EBITDA-Marge von über 20%.
- Adjusted EBITDA margin improved to 19.9% (+80 bps YoY)
- Healthcare segment grew 7.5% organically, with Surgery up 26.1% and Dental up 10.1%
- Segment gross profit margin increased 390 bps to 47.9%
- Free Cash Flow improved 50.9% YoY to CHF 11.4m
- Growth and Efficiency program secured CHF 15m in savings with CHF 8.5m already realized
- Revenue declined 6.5% YoY to CHF 225.4m
- Consumer & Industrial segment declined 10.9% organically
- Beauty business unit revenue fell 17.7% organically to CHF 73.8m
- Operating Net Cash Flow decreased 24.1% to CHF 15.3m
- Downward revision of 2025 revenue guidance
Ad hoc announcement pursuant to Art. 53 LR
| MEDIA RELEASE Baar, Switzerland--(Newsfile Corp. - July 23, 2025) - Ad hoc announcement pursuant to Art. 53 LR Half-Year 2025 Results |
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10892/259751_figure1.png
Increased profitability despite subdued revenues
HALF-YEAR 2025 HIGHLIGHTS
- Revenue at CHF 225.4m, -
6.5% (-4.6% organic FX adj.). Healthcare segment grew7.5% (organic FX adj.) driven by Dental and Surgery. Consumer & Industrial segment declined 10.9 % organic FX adj. on low commercial activity and project delays in Beauty - Adj. EBITDA margin at
19.9% , +80 bps YoY on higher Dental volume and continued gross profit margin improvements in Industry - Segment gross profit margin up 390 bps to
47.9% , positively impacting EBIT as a percentage of revenues (+170 bps) - Free Cash Flow at CHF 11.4m (+
50.9% yoy); Operating Net Cash Flow (ONCF) at CHF 15.3m
(-24.1% yoy) reflecting inventory build-up mainly in Dental to mitigate potential tariff impact - Well on track with Growth and Efficiency program: CHF 15m savings impact secured, CHF 8.5m realized in first half 2025 and 70 efficiency initiatives initiated
- Acceleration of cost out initiatives and CHF 3m additional actions identified, specifically targeted at Beauty business unit
- Strengthened leadership team: new CHRO, CTO and Business Unit Head Drug Delivery
- Revised 2025 revenue guidance: decline similar to that seen in H1 2025 (FX adj.)
Confirmed 2025 profitability guidance: adjusted EBITDA margin18% to19%
- Confirmed mid-term guidance: CAGR in revenue of above
4% , adj. EBITDA margin of above20%
CEO René Willi said: “We are on track with our strategy to pivot to high growth/high margin healthcare businesses. We have significantly improved profitability, which on the one hand is driven by strong growth in our most profitable Healthcare businesses Dental and Surgery, and on the other hand, by the impact of our Growth and Efficiency program. Our group revenues have been impacted by lower Beauty sales, which were the result of lower commercial activity, project delays and a high comparable in H1 2024. We have accelerated additional cost out measures of CHF 3m targeted at our Beauty business unit to maintain our high profitability levels.”
Revenue key figures
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10892/259751_figure2.png
GROUP REVIEW
In the first half of 2025, medmix generated revenue of CHF 225.4 million,
Healthcare segment revenue grew strongly in the first half of 2025, with two of the three Healthcare business units delivering robust year-on-year organic growth well above market rates, Surgery
Healthcare segment revenues increased by
Dental business unit organic revenue grew
Drug Delivery business unit revenue declined by
Surgery business unit revenue saw a
A continuation of the positive growth trajectory of the Dental and Surgery business units' revenue is expected in the second-half, at a more normalized level. The second source impact in the Drug Delivery business unit will again partly offset this growth.
Consumer & Industrial segment organic revenue declined by
Industry business unit revenue reached CHF 63.5 million in the first half of 2025, organically
Beauty business unit organic revenue declined year-on-year by
Gross profit margin, segment gross profit
Segment gross profit, which does not include shared cost and cost absorption, grew by
Healthcare segment gross profit increased by CHF 3.9 million, a growth of
Consumer & Industrial first-half segment gross profit decreased by
Adjusted EBITDA
Group Adjusted EBITDA was CHF 44.9 million, a decrease of
Net income
Net income increased by CHF 1.4 million to CHF 6.9 million (thereof CHF 6.8 million attributable to shareholders of medmix AG) from CHF 5.6 million (thereof CHF 5.2 million attributable to shareholders of medmix AG) in the prior period.
Operating Net Cash Flow (ONCF)
Operating Net Cash Flow for H1 2025 decreased to CHF 15.3 million compared to the same period a year ago (CHF 20.1 million) mainly due to inventory build-up in the Dental business unit while Free Cash Flow increased from CHF 7.6 million in H1 2024 to CHF 11.4 million in the first half of 2025, mainly due to lower CAPEX, which may however increase in the second half.
GROWTH & EFFICIENCY PROGRAM
Our Growth and Efficiency program launched in 2024 aims at enhancing growth by re-allocating resources to our strategic priorities and improving our performance by strategically reducing costs. With CHF 15 million savings impact secured and CHF 8.5 million realized in the first half of 2025, we are on track with our goal for H1 2025. We have implemented 70 efficiency initiatives, such as reducing headquarters and support functions or automating productions processes in our factories. We will also continue to invest in our sales organization and in R&D, which will ensure we remain at the forefront of innovation in both our segments. This program will not impact our ability to maintain our innovation pace and quality standards and will ultimately lead to an increase in our service levels.
STRENGTHENED LEADERSHIP TEAM
In the past half year, we have significantly strengthened our management team with seasoned leaders. Jasper Den Ouden joined medmix as of March this year as Chief Human Resources and Sustainability Officer. Jasper brings extensive international HR leadership experience. He most recently served as Chief Human Resources Officer at SR Technics Group in Zurich where he led HR for 2,200 employees and drove key initiatives in digital transformation, talent development, ESG and organizational change.
We are also very happy to welcome Francisco Faoro and Oliver Haferbeck to our Executive Leadership Team. Oliver was appointed as the new Head of Drug Delivery Business Unit in June. He brings a wealth of international leadership experience in the healthcare and medical technology sectors. Most recently, he served as Head of Gerresheimer Advanced Technology and CEO of Sensile Medical AG, where he led innovation in advanced drug delivery systems. His tenure at Gerresheimer was marked by a strong focus on strategic growth, technological advancement, and operational excellence.
Francisco Faoro joined medmix as Chief Technology Officer in May. Francisco brings extensive international leadership experience in technology and innovation. He held multiple senior leadership roles at Straumann Group, successfully preparing multiple implant innovations creating significant growth momentum. Prior to his tenure in the dental field, Francisco had several managerial positions in brand management and product development within the orthopedic and polymer processing industries.
OUTLOOK
Based on H1 2025 actuals and our outlook for the full year, we now expect a full year revenue decline similar to that seen in H1 2025 on an FX adjusted basis.
Our 2025 guidance for profitability with an adjusted EBITDA margin of 18
Key figures
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10892/259751_figure3.png
The medmix half-year report is available to download here.
Half-year 2025 results presentation
Webcast participation
medmix management will present the half-year results 2025 as a webcast on July 23, 2025, at 08:30 CET.
A webcast invitation was sent to medmix news subscribers early July. If you have not received it and wish to participate, please click here to pre-register by 08:00 CET latest to receive the link to the webcast and dedicated dial-in details.
Webcast playback
The playback of the webcast will be available shortly after the event under the same link.
Inquiries
Investor Relations: investorrelations@medmix.com
Media Relations: communications@medmix.com
Key dates in 2025/2026
| February 26, 2026 | Full-year results 2025 |
About medmix
medmix is a global leader in high-precision delivery devices. Our customers benefit from a dedication to innovation and technological advancement that has resulted in over 900 active patents. Our 14 production sites worldwide together with our highly motivated and experienced team of nearly 2,700 employees provide our customers with uncompromising quality, proximity, and agility. medmix is headquartered in Baar, Switzerland. Our shares are traded on the SIX Swiss Exchange (SIX: MEDX). www.medmix.swiss
Disclaimer
This document may contain forward-looking statements including, but not limited to, projections of financial developments, market activity, or future performance of products and solutions containing risks and uncertainties. These forward-looking statements are subject to change based on known or unknown risks and various other factors that could cause actual results or performance to differ materially from the statements made herein.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259751
FAQ
What were medmix's key financial results for H1 2025?
How did medmix's Healthcare segment perform in H1 2025?
What is medmix's revised guidance for 2025?
How much has medmix saved through its Growth and Efficiency program?
What caused the decline in medmix's Beauty business unit?
